Catalent adds position of president and chief operating officer to lead sales and quality efforts.
Catalent announced a leadership change in a Feb. 13, 2019 press release, naming Alessandro Maselli as president and chief operating officer, a new position within Catalent, reporting to John Chiminski, chair and CEO of Catalent. Maselli previously was the senior vice-president, global operations.
The company’s four business-unit presidents will report to Maselli, who will also oversee the leaders of global sales and marketing, and global quality and regulatory affairs. Management of the daily operations the company’s facilities will be integrated into the business units and administrative functions will continue to report to Chiminski.
“Catalent has enjoyed strong organic growth and integrated several strategic acquisitions since becoming a publicly traded company. We have now reached a stage where we can benefit from more executive team bandwidth to permit the necessary focus on both external opportunities and on operational excellence across our broad scope of businesses,” said Chiminski in a press statement announcing the appointment. “Alessandro will focus on the growth of our existing businesses, drive integration across our offerings, and meet customers’ ever-expanding needs for improved drug development and supply, while I will focus on long-term strategic growth, exploring future transformational opportunities as well as building deeper partnerships with investors, customers, suppliers, and other external constituencies.”
"I am honored to be given this opportunity,” said Maselli in the statement. “I am confident that we have everything we need to continue to win as we embark on this new chapter. We are expanding our global network, investing in growth-driving capabilities, and elevating our performance to help customers and patients around the world.”
Maselli joined Catalent in 2010 as director of operations at Catalent’s pharmaceutical, nutritional, and cosmetics plant in Aprilia, Italy. He served as manager of Zydis operations at Catalent’s facility in Swindon, UK and vice-president of operations, Europe, for Catalent’s Drug Delivery Solutions business unit.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.